Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4A2DQ
|
|||
| Drug Name |
SAGE-324
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Essential tremor or related tremors [ICD-11: 8A04.1; ICD-10: G25.0] | Phase 2 | [1] | |
| Parkinson disease [ICD-11: 8A00.0; ICD-10: G20] | Phase 1 | [2] | ||
| Company |
Sage Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor (GABAR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04305275) A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor. U.S. National Institutes of Health. | |||
| REF 2 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.